From molecular structure to Alzheimer therapy

Japanese Journal of Pharmacology

Volumn 74, Issue 3, 1997, Pages 225-241

  Giacobini, Ezio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alzheimer disease; Beta amyloid; Cholinesterase inhibitor

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BRAIN ENZYME; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; ESTROGEN; MUSCARINIC M1 RECEPTOR AGONIST; NICOTINIC AGENT;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DRUG DESIGN; HUMAN; NEUROPROTECTION; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 0030763602     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.225     Document Type: Review

References (87)

1. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long term treatment of senil dementia, Alzheimer type. N Engl J Med 315, 12451-1245 (1986)
2. Becker R, Moriearty P and Unni L: The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In Cholinergic Basis for Alzheimer Therapy, Edited by Becker R and Giacobini E, pp 263-296, Birkhäuser, Boston (1991)
3. Mattio T, McIlhany M, Giacobini E and Hallak M: The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology 25, 1167-1177 (1986)
4. Giacobini E, Becker R, Elble T, Mattio M, McIlhany M and Scarsella G: Brain acetylcholine - a view from the cerebrospinal fluid. In Neurobiology of Acetylcholine, Edited by Dun N, pp 85-101, Plenum Press, New York (1987)
5. Giacobini E: Models and strategies of cholinomimetic therapy of Alzheimer disease. In Cellular and Molecular Basis of Cholinergic Function, Edited by Dowdall MJ and Hawthorne JN, pp 882-901, Ellis Horwood, Chichester (1987)
6. Hallak M and Giacobini E: Relation of brain regional physostigmine concentrations to cholinesterase activity, and acetylcholine and choline levels in rat. Neurochem Res II, 1037-1048 (1986)
7. Giacobini E, Mussini I and Mattio T: Aging of cholinergic synapses: fiction or reality. In Dynamics of Cholinergic Function, Vol 30, pp 177-190, Edited by Hanin I, Plenum Press, New York (1986)
8. Checler F: Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65, 1431-1444 (1995)
9. Van Broeckhoven C: Presenilins and Alzheimer disease. Nature Genetics 11, 230-232 (1995)
10. Sandbrink R, Hartmann T, Masters CL and Beyreuther K: Genes contribution to Alzheimer's disease. Mol Psychiatry 1, 27-40 (1996)
11. 2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 271, 521-525 (1996)
12. Roses A: Perspective on the metabolism of apolipoprotein E and the Alzheimer disease. Exp Neurol 132, 149-156 (1995)
13. Giacobini E: Cholinesterase inhibitors do more than inhibit cholinesterase. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 187-204, Birkhäuser, Boston (1996)
14. Yankner B: New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nature Med 2, 850-852 (1996)
15. Soininen H and Riekkinen J Sr: Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci 19, 224-228 (1996)
16. Haroutunian V, Greig NH, Gluck R, Fiber E, Davis KL and Wallace WC: Selective attenuation of lesion-induced increases in secreted APP by acetylcholinesterase inhibitors. Soc Neurosci 21, 502 (1995)
17. Haroutunian V, Greig N, Pei XF, Utsuki L, Acevedo LD, Gluck R, Davis KL and Wallace D: Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Soc Neurosci 22, 1169 (1996)
18. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljärvi L, Talasniemi S, Ryynänen M and Riekkinen P: A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein E4 allele. Neurosci Lett 187, 79-82 (1995)
19. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM and Gauthier S: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92, 12260-12264 (1995)
20. Nordberg A: Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 57, 215-224 (1993)
21. Nordberg A: Long term treatment effects on progression of Alzheimer's disease as determined by functional brain studies. In Research Advances in Alzheimer's Disease and Related Disorders, Edited by Ikbal K, Mortimer JA, Winblad B and Wiesniewski HM, pp 293-298, John & Sons, Chichester (1995)
22. Gracon S, Smith F and Hoover T: Long-term tacrine treatment: effect on nursing home placement and mortality. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 205-209, Birkhäuser, Boston (1996)
23. Thornton JE and Gershon S: The history of THA. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 267-278, Taylor and Francis, New York (1988)
24. Sussmann JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L and Silman I: Atomic structure of acetylcholinesterase from Torpedo Californica: a prototypic acetylcholine binding protein. Science 253, 872-874 (1991)
25. Brufani M and Filocamo L: Rational design of new acetylcholinesterase inhibitors. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 171 -177, Birkhäuser, Boston (1996)
26. Moriearty PL and Becker R: Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Methods Find Exp Clin Pharmacol 14, 615-621 (1992)
27. Ogane N, Giacobini E and Messamore E: Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 17, 489-495 (1992)
28. Ogane N, Giacobini E and Struble R: Differential inhibition of acetylcholinsterase molecular forms in normal and Alzheimer disease brain. Brain Res 589, 307-312 (1992)
29. Anand R, Hartman RD and Hayes PE: An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 239-243, Birkhäuser, Boston (1996)
30. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski CH and Dolan-Ureno J: A controlled trial of tacrine in Alzheimer's disease. JAMA 268, 2523-2529 (1992)
31. Knapp MJ, Knopman DS and Solomon PR: A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271, 985-991 (1994)
32. Roger SL and Friedhoff T: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7, 293-303 (1996)
33. Becker R, Moriearty P, Unni L and Vicari S: Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 257-266, Birkhäuser, Boston (1996)
34. Giacobini E, Becker R, McIlhany M and Kumar V: Intracerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 113-122, Taylor and Francis, New York (1988)
35. Giacobini E: Cholinesterase inhibitors. From preclinical studies to clinical efficacy in Alzheimer disease. In Enzymes of the Cholinesterase Family, Edited by Quinn D, Balasubramaniam AS, Doctor BP and Taylor P, pp 463-469, Plenum Press, New York (1995)
36. Giacobini E, DeSarno P, Clark B and McIlhany M: The cholinergic receptor system of the human brain - neurochemical and pharmacological aspects in aging and Alzheimer. Prog Brain Res 79, 335-343 (1989)
37. Giacobini E and Cuadra G: Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In Alzheimer Disease: Therapeutic Strategies, Edited by Giacobini E and Becker R, pp 155-171, Birkhäuser, Boston (1994)
38. Giacobini E: Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? In Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction, Edited by Racagni G, Brunello N and Langer SZ, Vol 7, pp 51-57, Int Acad Biomed Drug Res, Karger, New York (1994)
39. Rupniak NMJ, Field MJ, Samson NA, Steventon MJ and Iversen SD: Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 11, 609-613 (1990)
40. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P, Perdhal E, Wester P and Winblad B: Transmitter deficits in Alzheimer's disease. Neurochem Int 7, 545-563 (1985)
41. Decker MW and McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168 (1991)
42. Messamore E, Warpman U, Williams E and Giacobini E: Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition. Neurosci Lett 158, 205-208 (1993)
43. Silver A: The biology of cholinesterases. In Frontiers of Biology, Vol 36, pp 426-447, Edited by Neuberger A and Tatum EL, North Holland Publ, Amsterdam, Elsevier Sci Publ, New York (1974)
44. Giacobini E and Holmstedt: Cholinesterase content of certain regions of the spinal cord as judged by histochemical and cartesian diver technique. Acta Physiol Scand 42, 12-27 (1958)
45. Giacobini E: Distribution and localization of cholinesterases in nerve cells. Acta Physiol Scand 45, supp 156, (1959)
46. Giacobini E: Metabolic relations between glia and neurons studied in single cells. In Morphological and Biochemical Correlates of Neural Activity, Edited by Maynard M, Cohen MD and Snider R, pp 15-38, Harper & Row, New York (1964)
47. Wright CI, Geula C and Mesulam MM: Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann Neurol 34, 373-384 (1993)
48. Perry EK, Perry RH, Blessed G and Tomlinson BE: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4, 273-277 (1978)
49. Arendt T, Brückner MK, Lange M and Bigl V: Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms. J Neurochem 21, 381-396 (1992)
50. Davies P: Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171, 319-327 (1979)
51. Atack JR, Perry EK, Bonham JR, Candy JM and Perry RH: Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem 48, 1687-1692 (1987)
52. Atack JR, Perry EK, Bonham JR, Candy JM and Perry RH: Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47, 263-277 (1986)
53. Arendt T, Bigl V, Walter F and Sonntag M: Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase in Alzheimer's disease. Lancet 1, 173 (1984)
54. Shafferman A, Velan B, Ordentlich A, Kronman C, Grosfeld H, Leitner M, Flashner Y, Cohen S, Barak D and Ariel N: Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. Embo J 11, 3561-3568 (1992)
55. Giacobini E, Zhu X-D, Williams E and Sherman KA: The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amines levels in rat cortex. Neuropharmacology 35, 205-211 (1996)
56. Cuadra G, Summers K and Giacobini E: Cholinesterase inhibitor effects on neurotransmitters in rat cortes in vivo. J Pharmacol Exp Ther 270, 277-284 (1994)
57. Massoulié J and Toutant JP: Vertebrates ChEs: structure and types of interaction. In Handbook of Experimental Pharmacology, Edited by Whittaker VP, Vol 86, The Cholinergic Synapse, pp 167-224, Springer Verlag, Berlin-Heidelberg (1988)
58. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Master CL, Grzeschil K-H, Multaup G, Beyreuther K and Muller-Hill B: The precursor of Alzheimer disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736 (1987)
59. Beeson JG, Shelton ER, Chan HW and Gage FH: Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. J Comp Neurol 342, 78-96 (1994)
60. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A and Price DL: Evidence that beta amyloid protein in Alzheimer disease is not derived by normal processing. Science 248, 492-495 (1990)
61. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH: Release of Alzheimer precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307 (1992)
62. Buxbaum JD, Oishi M, Chen Hl, Pinkas-Kramarski R, Jaffe EA, Gandy SE and Greengard P: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer βA4 amyloid protein precursor. Proc Natl Acad Sci USA 89, 10075-10078 (1992)
63. Buxbaum JD: Post-translational control of the amyloid β-protein precursor processing. In Pathobiology of Alzheimer's Disease, pp 98-114, Academic Press Limited, New York (1995)
64. Nitsch RM and Growdon JH: Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. Biochem Pharmacol 47, 1275-1284 (1994)
65. Lahiri DK, Lewis S and Farlow MR: Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 37, 777-787 (1994)
66. Chong YH and Suh YH: Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci 59, 545-557 (1996)
67. Mori F, Lai CC, Fusi F and Giacobini E: Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6, 633-636 (1995)
68. Nitsch RM, Farber SA, Growdon JH and Wurtman RJ: Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci USA 90, 191-193 (1993)
69. Chong YH, Jung JM, Choi W, Park CW, Choi KS and Suh YH: Bacterial expression, purification of full length and carboxyl fragment of Alzheimer amyloid precursor protein and their proteolytic processing by thrombin. Life Sci 54, 1259-1268 (1994)
70. Giacobini E, Mori F, Buznikov A and Becker R: Cholinesterase inhibitors alter APP secretion and APP mRNA in rat cerebral cortex. Soc Neurosci Abstr 21, 988 (1995)
71. Anderson JP, Refolo LM, Wallace W, Mehta P, Krishnamurthi M, Gotlib J, Bierer L, Haroutunian V, Perl D and Robakis NK: Differential brain expression of the Alzheimer's amyloid precursor protein. EMBO J 8, 3627-3632 (1989)
72. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva O, Soto C and Garrido J: AChE accelerates assembly of amyloid-β peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16, 881-891 (1996)
73. Small DH, Moir RD, Fuller SJ, Michaelson S, Bush A, Qiao-Xin L, Milward E, Hilbich C, Weidemann A, Beyreuther K and Colin Masters L: A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease. Biochemistry 30, 10795-10799 (1991)
74. Funes S: Acétylcholinestérase et Maladie d'Alzheimer. Thèse présentée pour obtenir le grade de Docteur de l'Université de Louis Pasteur, Strasbourg (1996) (in French)
75. Chong YH, Jung JM, Choi W, Park CW, Soc Choi K and Suh YH: Bacterial expression, purification of full length and carboxyl terminal fragment of Alzheimer amyloid precursor protein and their proteolytic processing by thrombin. Life Sci 54, 1259-1268 (1994)
76. Wallace WC, Bragin V, Robakis NK, Sambamurti K, Vander-Putten D, Merril CR, Davis KL, Santucci AC and Haroutunian V: Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Mol Brain Res 10, 173-178 (1991)
77. Nordberg A: Pet imaging of nicotinic receptors in Alzheimer's disease - implication with diagnosis and drug treatment. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 439-444, Birkhäuser, Boston (1996)
78. Minthon L, Nilsson K, Edvinsson L, Wendt PE and Gustafson L: Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's Disease. Dementia 6, 245-251 (1995)
79. Canal I and Imbimbo BP: Clinical trials and therapeutics: Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 60, 1-11 (1996)
80. Imbimbo BP: Eptastigmine: A cholinergic approach to the treatment of Alzheimer's disease. In Alzheimer Disease: From Molecular Biology to Therapy, Edited by Becker R and Giacobini E, pp 223-230, Birkhäuser, Boston (1996)
81. Thai L, Fuld PA, Masur DM and Sharpless NS: Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13, 491-496 (1983)
82. Imbimbo BP and Lucchelli PE: A pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). In Alzheimer Disease: Therapeutic Strategies, Edited by Giacobini E and Becker R, pp 103-107, Birkhäuser, Boston (1994)
83. Becker R, Colliver J and Elble R: Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 19, 425-434 (1990)
84. Knapp S, Wardlow ML, Albert W, Waters D and Thai J: Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos 19, 400-404 (1991)
85. Zuh XD, Cuadra G, Brufani M, Maggi T, Pagella PG, Williams E and Giacobini E: Effects of MF268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex. J Neruosci Res 43, 120-126 (1996)
86. Zhu XD, Giacobini E and Hornsperger JM: Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex. Eur J Pharmacol 276, 93-99 (1995)
87. Mori F, Cuadra G and Giacobini E: Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 20, 1081-1088 (1995)